Evidence map›Paper›PMID 34358128›Full record

ReviewVaccines2021

Bridging the B Cell Gap: Novel Technologies to Study Antigen-Specific Human B Cell Responses.

Henry A Utset, Jenna J Guthmiller, Patrick C Wilson

Abstract readReview
In one paragraph

Review in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Henry A UtsetDepartment of Medicine, Section of Rheumatology, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0003-0607-3086
Jenna J GuthmillerDepartment of Medicine, Section of Rheumatology, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0001-7566-3536
Patrick C WilsonDepartment of Medicine, Section of Rheumatology, University of Chicago, Chicago, IL 60637, USA.

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
VACCINE INDUCED IMMUNITY IN THE YOUNG AND AGEDU19AI057266 · NIAID · EMORY UNIVERSITY · PI Rafi Ahmed · 2003 to 2026
$81.7M
RESEARCH TRAINING IN RESPIRATORY BIOLOGYT32HL007605 · NHLBI · UNIVERSITY OF CHICAGO · PI Yun Fang, Gokhan M. Mutlu · 1985 to 2026
$18.1M
Understanding Human B Cell Responses to Influenza to Improve the Influenza U19AI109946 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI RAVETCH, JEFFREY VICTOR · 2014 to 2018
$9.6M
University of Chicago Autoimmunity Center of ExcellenceU19AI082724 · NIAID · UNIVERSITY OF CHICAGO · PI CLARK, MARCUS RAMSAY · 2009 to 2023
$7.2M
National Institute of Allergy and Infectious Diseases U19AI057266National Institute of Allergy and Infectious Diseases U19AI082724National Institute of Allergy and Infectious Diseases U19AI109946NHLBI NIH HHS T32HL007605-35NIAID NIH HHS 75N93019C00051NIAID NIH HHS HHSN272201400005C
6 · The paper itself

Abstract

The generation of high affinity antibodies is a crucial aspect of immunity induced by vaccination or infection. Investigation into the B cells that produce these antibodies grants key insights into the effectiveness of novel immunogens to induce a lasting protective response against endemic or pandemic pathogens, such as influenza viruses, human immunodeficiency virus, or severe acute respiratory syndrome coronavirus-2. However, humoral immunity has largely been studied at the serological level, limiting our knowledge on the specificity and function of B cells recruited to respond to pathogens. In this review, we cover a number of recent innovations in the field that have increased our ability to connect B cell function to the B cell repertoire and antigen specificity. Moreover, we will highlight recent advances in the development of both ex vivo and in vivo models to study human B cell responses. Together, the technologies highlighted in this review can be used to help design and validate new vaccine designs and platforms.

Indexed as

B cell repertoiresbone marrowbroadly neutralizing antibodiesfine needle aspiratesgerminal centerhuman B cellshumanized micehumoral immunitylymph nodeRNA-sequencing

Identifiers

PMID34358128
PMCPMC8310089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.